EUCTR2011-005344-95-DK进行中（未招募）1 期
Time course of the blood pressure lowering effect of liraglutide therapy in type 2 diabetes - Liratime
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Must give written informed consent before participation. Patient information and consent form must be approved by the Danish Medicines Agency and the Regional Scientific Ethical Committee
- •2.Male or female patients >18 years with type 2 diabetes (WHO criteria).
- •3.Patients must be on treatment with metformin. Any form of treatment with SU compounds will be discontinued and washed out for two weeks prior to the start of study drug.
- •4.HbA1c > 6.5%
- •5.eGFR = 60 ml/min/1.73 m2 (estimated by MDRD formula)
- •6.Fertile female patients must use chemical, hormonal and mechanical contraceptives or be in menopause (i.e. must not have had regular menstrual bleeding for at least one year) or have undergone bilateral oophorectomi or have been surgically sterilized or hysterectomised at least six months prior to screening
- •7.Patients must be on antihypertensive treatment or having elevated blood pressure (SBP =130 mm Hg and DBP =80 mmHg), lower than 170/105 mm Hg at baseline and the patients must be stable antihypertensive medication for at least 4 weeks prior to baseline
- •8.Patients must be on stable hypoglycemic medication for at least two weeks before the first visit.
- •9.Must be able to communicate with the investigator
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 5
排除标准
- •1.Ongoing insulin therapy
- •2.BP > 170/105 mm Hg at baseline
- •3.Type 1 diabetes mellitus
- •4.Chronic pancreatitis / previous acute pancreatitis
- •5.Known or suspected hypersensitivity to trial product(s) or related products.
- •6.Treatment with oral glucocorticoids, calcineurin inhibitors, or dipeptidyl peptidase 4 (DPP4) inhibitors which in the Investigator’s opinion could interfere with glucose or lipid metabolism 90 days prior to screening
- •7.Cancer (except basal cell skin cancer or squamous cell skin cancer) or any other clinically significant disorder, except for conditions associated with type 2 diabetes history, which in the investigators opinion could interfere with the results of the trial
- •8.Inflammatory bowel disease
- •9.Cardiac disease defined as: Decompensated heart failure (NYHA class III-IV) and/or diagnosis of unstable angina pectoris and/or myocardial infarction within the last 6 months
- •10.Previous bowel resection
- •11.Body mass index <18.5 kg/m2
- •12.Females of childbearing potential who are pregnant, breast-feeding, intend to become pregnant or are not using adequate contraceptive methods
- •13.Clinical signs of diabetic gastroparesis
- •14.Impaired liver function (transaminases > two times upper reference levels)
- •15.The receipt of any investigational product 90 days prior to this trial
- •16.Known or suspected abuse of alcohol or narcotics
- •17.Subjects with personal or family history of medullary thyroid carcinoma or a personal history of multiple endocrine neoplasia type 2
研究者
相似试验
已完成
不适用
Short-term effects on blood pressure of reducing nitrate metabolism using antibacterial mouthwash in treated hypertensive individualsHypertensionCardiovascular diseaseACTRN12613000417785The University of Western Australia25
已完成
Unknown
Study on the effect of blood pressure suppression by single intake of test foodsHealthy AdultsJPRN-UMIN000053620Healthcare Systems Co., Ltd.4
招募中
不适用
The relationship between blood pressure reduction by standing and respiratory muscleOrthostatic hypotensionJPRN-UMIN000028450Kochi University40
已完成
2 期
The Effect of Blood Pressure improvement on memory function of Senior Citizens with Low Blood Pressure and mild memory impairment.CTRI/2014/12/005298KMC MANGALORE MANIPAL UNIVERSITY80
已完成
不适用
Study of effect of blood pressure suppression by intake of MekabuHealthy AdultsJPRN-UMIN000046597Healthcare Systems Co., Ltd.60